| 研究課題/領域番号 |
20J20737
|
|---|
| 研究機関 | 北海道大学 |
|---|
研究代表者 |
Abd Elwakil Mahmoud 北海道大学, 生命科学院, 特別研究員(DC1)
|
|---|
| 研究期間 (年度) |
2020-04-24 – 2023-03-31
|
| キーワード | mRNA drugs / ionizable polyesters / Gene Therapy / Organocatalysis / Lipid Nanoparticles / Lung diseases / Combinatorial chemistry / Immunotherapy |
|---|
| 研究実績の概要 |
During the past year I have developed a novel platform for mRNA delivery beyond the hepatocytes referred as to ionizable polyester/polyether RNA-Transporters (iPORT LNP). The key findings for the past year are:
1. Development of ionizable lipo-polyether RNA transporters (iPORTs) that are produced via the organocatalytic ring-opening polymerization of glycidylamine monomers using steroidal initiators. Interestingly, the tacticity of the iPORTs had a significant impact on in vitro and in vivo RNA delivery efficiency and tropism and this impact was dependent of monomeric structure. The top performing Estriol-GA05-30 iPORT LNPs elicited strong antitumor activity in a therapeutic, prophylactic model and were well-tolerated in mice. This technology is being filed as a patent through Hokkaido University. Additionally a manuscript has been submitted to JACS, Manuscript ID: ja-2022-017103).
2. Development of ionizable polyester RNA-Transporters LNP that selectively transfect splenocytes and lungs after systemic administration. The results of this project is being filed as a patent through Hokkaido University as well. Furthermore, a manuscript is being prepared for submission to publications.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
Although we are at very hard times during COVID-19, my research projects were going very well and research output was really great because:
1. I have submitted two patents in one year.
2. Two manuscripts were prepared and are being submitted for publication in top tier scientific journals.
|
| 今後の研究の推進方策 |
In the coming year I plan to:
1. Apply my mRNA iPORT LNP technology for therapeutic application in lung diseases, cancer immunotherapy and infectious diseases vaccines such as COVID-19.
2. Extend my combinatorial chemistry for RNA delivery for other hard tissues such as bone and central nervous system.
3. Communicate my iPORT LNP technology with scientific community via attending international conferences and big pharmaceutical companies.
|
